Healthcare Sector

ABBV

Market Tracker

$198.47
+5.13
(+2.65%)
4:00 am
Next Earnings: (est.) 07/27/23 12:00 am
  • ABBV (Selected)

    AbbVie Inc.

ABBV Support / Resistance Levels

Loading Data..
WhaleStream

15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.

ABBV Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

ABBV Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

ABBV Dark Pool and Public Equity Key Price Levels

Loading Data..

Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.

ABBV Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

ABBV Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
06/20/2025 CALL $195.00 1,561 +1,500 +2,459.02%
06/20/2025 PUT $195.00 1,500 +1,500
06/20/2025 CALL $210.00 8,958 +302 +3.49%
05/02/2025 CALL $197.50 683 +265 +63.40%
05/02/2025 PUT $190.00 542 +238 +78.29%
08/15/2025 PUT $195.00 1,438 +203 +16.44%
05/02/2025 CALL $192.50 717 -23 -3.11%
05/16/2025 CALL $200.00 9,431 -42 -0.44%
05/02/2025 CALL $190.00 371 -73 -16.44%
05/16/2025 CALL $175.00 2,997 -76 -2.47%
06/20/2025 PUT $150.00 4,374 -417 -8.70%
05/16/2025 CALL $182.50 265 -515 -66.03%

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

ABBV Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 3.05% 53.76M 7.26B
Vanguard 500 Index Fund 2.32% 40.88M 5.52B
Fidelity 500 Index Fund 1.10% 19.39M 2.62B
SPDR S&P 500 ETF Trust 1.09% 19.15M 2.58B
American Mutual Fund Inc 1.00% 17.6M 2.38B
iShares Core S&P 500 ETF 0.89% 15.78M 2.13B
Vanguard Index-Value Index Fund 0.87% 15.28M 2.06B
Capital Income Builder, Inc. 0.84% 14.87M 2.01B
Select Sector SPDR Fund-Health Care 0.81% 14.36M 1.94B
Washington Mutual Investors Fund 0.75% 13.22M 1.78B

ABBV News

  • 3 Dividend Stocks to Buy and Hold for the Next Decade

    04/28 07:47 am

    The Motley Fool

    Read more
  • Should Investors Be Worried About Dividend King AbbVie?

    04/28 04:42 am

    The Motley Fool

    Read more
  • 4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off

    04/26 06:05 pm

    The Motley Fool

    Read more
  • Why AbbVie Stock Topped the Market Today

    04/25 05:17 pm

    The Motley Fool

    Read more
  • Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday

    04/22 05:37 pm

    The Motley Fool

    Read more
  • Is AbbVie Stock a Buy?

    04/20 08:15 am

    The Motley Fool

    Read more
  • ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE

    04/18 05:12 pm

    GlobeNewswire Inc.

    Read more
  • Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market

    04/18 04:26 am

    GlobeNewswire Inc.

    Read more
  • ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE

    04/14 05:33 pm

    GlobeNewswire Inc.

    Read more
  • Male Hypogonadism Market Forecast Report and Company Analysis 2025-2034 Featuring AbbVie, Bayer, Eli Lilly, Endo, Ferring, Perrigo, Pfizer, Sanofi, Teva, and Viatris

    04/10 10:00 am

    GlobeNewswire Inc.

    Read more
  • Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline

    04/10 05:59 am

    GlobeNewswire Inc.

    Read more
  • 2 Top Dividend Stocks That Could Set You Up for Life

    04/09 07:00 am

    The Motley Fool

    Read more
  • Dr. Oz Officially Confirmed as Head of the Centers for Medicare and Medicaid Services. Here's What Retirees Need to Know So Far.

    04/09 05:44 am

    The Motley Fool

    Read more
  • Ophthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities

    04/08 04:52 am

    GlobeNewswire Inc.

    Read more
  • Global Cosmeceuticals Market Size to Reach USD 182.17 Bn by 2032, at a CAGR of 9.6%, says Coherent Market Insights

    04/08 12:50 am

    GlobeNewswire Inc.

    Read more
  • 3 Dividend Stocks to Buy and Hold for the Next Decade

    04/06 06:44 am

    The Motley Fool

    Read more
  • 2 Dividend Stocks to Buy Hand Over Fist in April

    04/05 08:30 am

    The Motley Fool

    Read more
  • Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More

    04/03 12:30 pm

    Benzinga

    Read more
  • Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.

    03/31 04:53 am

    The Motley Fool

    Read more
  • Global Autoimmune Disease Therapeutics Market to reach USD 226,194.0 Million by 2035 Amid Rising Prevalence and Advancements in Biologic Therapies | Future Market Insights, Inc.

    03/23 08:30 pm

    GlobeNewswire Inc.

    Read more
  • Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

    03/21 11:29 pm

    GlobeNewswire Inc.

    Read more
  • Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends

    03/20 09:31 am

    The Motley Fool

    Read more
  • AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients

    03/17 02:02 pm

    Benzinga

    Read more
  • 5 Reasons the Schwab U.S. Dividend Equity ETF Is a Long-Term Buy for 2030 and Beyond

    03/17 07:45 am

    The Motley Fool

    Read more
  • 1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction

    03/16 06:19 pm

    The Motley Fool

    Read more
  • 3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

    03/14 05:51 am

    The Motley Fool

    Read more
  • Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - Global Forecast to 2030

    03/12 11:50 am

    GlobeNewswire Inc.

    Read more
  • Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

    03/11 07:30 am

    GlobeNewswire Inc.

    Read more
  • Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas

    03/10 04:53 pm

    The Motley Fool

    Read more
  • Is the Vanguard High Dividend Yield ETF the Smartest Investment You Can Make Today?

    03/10 06:11 am

    The Motley Fool

    Read more
  • Is the SPDR S&P 500 ETF Trust the Smartest Investment You Can Make Today?

    03/09 12:10 pm

    The Motley Fool

    Read more
  • 3 Cheap Stocks to Buy With Your Tax Refund Check

    03/07 06:30 am

    The Motley Fool

    Read more
  • AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race

    03/03 03:07 pm

    Benzinga

    Read more
  • OPZELURA Continues to Revolutionize Dermatology Market with Strong Market Uptake | DelveInsight

    02/28 02:00 pm

    GlobeNewswire Inc.

    Read more
  • Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

    02/27 06:47 am

    The Motley Fool

    Read more
  • Non-Small Cell Lung Cancer Market Set for Significant Growth Across the 7MM During the Study Period (2025-2034) Due to the Rising Novel Therapeutic Options | DelveInsight

    02/26 02:00 pm

    GlobeNewswire Inc.

    Read more
  • DURYSTA’s Market Potential Across the 7MM is Set to Soar During the Study Period (2020–2034) as a Game-Changer in Ophthalmic Care | DelveInsight

    02/26 02:00 pm

    GlobeNewswire Inc.

    Read more
  • Questex’s Fierce Pharma Unveils the Conference Program for the Inaugural Fierce Pharma Engage, Over 100 Speakers Confirmed to Deliver Unparalleled Education

    02/24 11:00 am

    GlobeNewswire Inc.

    Read more
  • BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment

    02/20 02:00 pm

    GlobeNewswire Inc.

    Read more
  • Antibody-Drug Conjugates Market to Witness Rapid Growth Across 7MM During the Study Period (2020–2034) as New Innovations Drive Therapy Advancements | DelveInsight

    02/20 02:00 pm

    GlobeNewswire Inc.

    Read more
  • 2 Magnificent Dividend Growth Stocks to Load Up On Right Now

    02/20 06:30 am

    The Motley Fool

    Read more
  • 4 Stocks and 1 Exchange-Traded Fund (ETF) I Can't Stop Buying

    02/19 11:42 am

    The Motley Fool

    Read more
  • Want Decades of Passive Income? Buy This ETF and Hold It Forever.

    02/18 07:15 am

    The Motley Fool

    Read more
  • Is AbbVie Stock a Buy Now?

    02/15 05:55 am

    The Motley Fool

    Read more
  • Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

    02/13 02:00 pm

    GlobeNewswire Inc.

    Read more
  • 3 Stocks That Missed on Earnings, but Are Set to Rebound Next Quarter

    02/11 08:18 am

    Investing.com

    Read more
  • 3 Fabulous Dividend Stocks to Buy in February

    02/09 03:30 pm

    The Motley Fool

    Read more
  • 3 Dividend Stocks to Double Up on Right Now

    02/09 06:43 am

    The Motley Fool

    Read more
  • These 2 Dividend Stocks Are Absolute Bargains Right Now

    02/08 09:30 am

    The Motley Fool

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: